Close Menu

Somalogic

A company researcher said the new structure could provide the chemical diversity needed to build a set of reagents targeting the full human proteome.

The bioinformatics startup has also invested in six other companies, committing $400 million to its data-sharing collaboration.

The company has identified markers of latent disease that it is now investigating to see if they could be useful for predicting progression to active infection.

The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.  

The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.

The company this week published a study in JAMA describing the panel, which is intended for assessing the risk of adverse events in coronary heart disease patients.

The firm said it will use the funds to support development of new life science tools and clinical diagnostics based on its Somamer affinity agent technology.

While SomaScan is the company's main source of revenue, it continues to develop its Dx business and will launch its first test in the second half of 2016.

Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.

Pacific Biosciences announced this week that it has reached the final developmental milestone of its commercialization and licensing agreement with Roche.

Pages

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.